logo
About Contact

FDA Issues New Warnings for GLP-1 Weight-Loss Drugs Amid Rare Vision Loss Concerns

World News

FDA Issues New Warnings for GLP-1 Weight-Loss Drugs Amid Rare Vision Loss Concerns

FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

CNBC

FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

Ozempic, Wegovy and other GLP-1 drugs to carry vision loss warning after FDA finds rare eye risk

Hindustan Times

Ozempic, Wegovy and other GLP-1 drugs to carry vision loss warning after FDA finds rare eye risk

US regulators say the rare eye condition NAION can cause permanent vision loss. All GLP-1 drugs, including Ozempic and Wegovy, will now carry the warning.

GLP-1 Drugs Receive New Warning Labels Over Rare Blindness Risk

NDTV

GLP-1 Drugs Receive New Warning Labels Over Rare Blindness Risk

The new alert aims to warn patients and doctors about a rare eye condition that can lead to sudden, permanent vision loss

Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?

CNBC

Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?

Novonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, opening up a potentially lucrative new market.

US is requiring weight-loss drug makers to warn about possible loss of eyesight

Independent

US is requiring weight-loss drug makers to warn about possible loss of eyesight

Nearly 30 million Americans are taking weight-loss drugs

Coverage dates

First reported:

First saved on ClustZ:

Coverage updated:

We use cookies to improve your experience and analyze site traffic. By clicking "Accept", you agree to our use of cookies. See our Privacy Policy.